IR News
This document provides integrated information to the media. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
-
FinancesFY2026 Second Quarter Results Briefing Session - Script
-
FinancesFY2026 Second Quarter Results Briefing Session - Movie
-
FinancesFY2026-Q2 Financial Report (Jul. 1-Sep. 30, 2026)
-
FinancesFY2026 Second Quarter Results Briefing Session - Material
-
CorporateNotice of Personnel ChangeView PDF
-
ProductsJCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter SyndromeView PDF
-
LicensingItalfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin AmericaView PDF
-
CorporateNotice of Organizational and Personnel ChangesView PDF
-
R&DJCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular DystrophyView PDF
-
OtherIntegrated Report 2026